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Abstract
Background: Apolipoprotein B100 (apoB) is a superior indicator of CV risk than total or LDL-C. Non-HDL-C
represents a simple surrogate for apoB in hypertriglyceridemic and/or T2DM patients. ApoB and non-HDL-C show
high correlation, although the degree of mutual concordance remains debated in CV risk evaluation.
Objectives: We used the Discriminant Ratio (DR) methodology to compare the performance of non-HDL-C with
that of apoB to rank diabetic patients according to dyslipidemia and to establish the underlying relationship
between these variables taking measurement noise and intra-/intersubject variation into account, and to derive an
unbiased equivalence equation.
Methods: Fasting total C, HDL-C, apoB and triglycerides were measured in 45 diabetic patients. The DR of the
underlying between-subject standard deviation (SD) to the within-subject SD was calculated from duplicates.
Correlation coefficients between pairs were adjusted to include an estimate of the underlying correlation.
Results: Mean values [day 1 (1SD)] were 143 (36) mg/dl (non-HDL-C) and 98 (24) mg/dl (apoB). The DR’s of both
parameters were similar (1.76 and 1.83) (p = 0.83). Pearson’s product-moment correlation coefficient between tests
was very high (0.94), reaching unity (1.00) after attenuation adjustment. The unbiased equation of equivalence
relating apoB to non-HDL-C had a slope of 0.65 and an intercept of 6.3 mg/dl.
Conclusions: The discrimination power of non-HDL-C is similar to that of apoB to rank diabetic patients according
to atherogenic cholesterol and lipoprotein burden. Since true correlation between variables reached unity, non-
HDL-C may provide not only a metabolic surrogate but also a candidate biometrical equivalent to apoB, as non-
HDL-C calculation is readily available.
Introduction
Total cholesterol and low-density lipoprotein cholesterol
(LDL-C), the major component of the former, represent
key standard modifiable risk factors for atherosclerotic
cardiovascular disease. The hallmark of atherogenic dys-
lipidemia is low levels of high-density lipoprotein cho-
lesterol (HDL-C) as well as elevated triglycerides (TG)
levels, while LDL-C level may only be marginally ele-
vated in this setting [1,2]. A single apolipoprotein B100
(apoB) molecule is present in all major atherogenic par-
ticles of liver origin (very-low and intermediate-density
lipoproteins (VLDL and IDL), and LDL). Therefore,
measurement of apoB provides direct information
on the number of atherogenic particles (LDL and
non-LDL), irrespective of their size. Further, these
atherogenic particles, collectively known as non-HDL
lipoproteins, are associated with atherogenic dyslipide-
mia, insulin resistance, portal hyperinsulinemia and the
metabolic syndrome phenotype [3-11]. Various ratios
were introduced to increase epidemiological prediction
of cholesterol, and include the ratio of total or LDL-C
to HDL-C, and that of apoB to apoA-I, which represents
the ratio of the level of prograde, liver-derived, choles-
terol-transporting, major lipoprotein divided by the level
of retrograde, reverse cholesterol-transporting lipopro-
tein [12-15].
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fasting conditions, these apolipoproteins are not cur-
rently part of routine laboratory lipid assessment. Yet, it
is now established that both apoB measurement and
non-HDL-C (often considered a surrogate of the former,
and easily obtained from subtracting HDL-C from C)
are better predictors of CVD that LDL-C (even when
the latter is directly measured instead of derived from
Friedewald’s formula), evidence which should eventually
lead to some revision of the current risk paradigm
[3-11].
Non-HDL-C was introduced as another means to
refine risk estimation beyond LDL-C from Friedewald’s
formula in the presence of raised triglycerides (TG)
levels (≥200 mg/dl), since associated changes in VLDL-
TG/VLDL-C ratio may lead to LDL-C undercalculation
[2]. As it actually estimates the level of all apoB-carrying
lipoproteins, non-HDL-C may represent a simple and
inexpensive surrogate to apoB measurement, especially
in selected patients groups, such as hypertriglyceridemic
patients and/or patients with diabetes. The current
debate focuses on which of the two should be deter-
mined, and in which specific subgroups. It was sug-
gested that apoB might be more performant in
identifying patients at CVD risk in the low-risk range
and/or in normotriglyceridemic patients, whereas non-
HDL-C may be more appropriate in higher-risk patients
or in the setting of elevated triglycerides levels or cardi-
ometabolic states [3-5,7,16-18].
ApoB and non-HDL-C measurement show high corre-
lation, although mutual concordance remains a subject of
debate in CV risk evaluation. While correlation between
apoB and non-HDL-C is reckoned very high, the issue of
concordance, agreement and equivalence of use for pre-
dicting risk in diabetic patients remains controversial
[3-5]. The present study uses the Discriminant Ratio
(DR) methodology developed by Levy et al.t oc o m p a r e
the performance of non-HDL-C to that of apoB to rank
diabetic patients according to spread of individual lipid
values, from normal to dyslipidemia [19-21]. Levy et al.
methodology standardises comparisons of imprecise tests
by taking into account fundamental properties for asses-
sing imprecision and practical performance of tests
designed to measure similar physiological variables. This
three-steps comparison approach requires (i) establishing
a discriminant ratio and relative discriminant power; (ii)
determining the maximum expected rank correlation
with another test taking measurement noise into account;
and (iii) defining an unbiased line of equivalence relating
non-HDL-C to apoB.
Methods and statistical analysis
We studied 45 consecutive North-Caucasian subjects
with diabetes mellitus (type 1; n = 23 and type2; n = 22)
and a wide range of atherogenic cholesterol and athero-
genic particles number values, from normal to various
degrees of (un)treated dyslipidemia, representing a prac-
tical range of lipid values as observed in clinical cardiol-
ogy or diabetes settings.
All lipid values were obtained in the fasting state on
2 different, non-consecutive days. The time-span
between samples was 1-3 months, as they were taken
during regular outpatients follow-up visits, with lipid-
lowering drugs neither prescribed, introduced, switched
nor titrated between duplicate samplings. Total choles-
terol and triglycerides were determined using SYN-
CHRON
® system (Beckman Coulter Inc., Brea, CA).
HDL-C was determined with ULTRA-N-geneous
®
reagent (Genzyme Corporation, Cambridge, MA).
ApoB was determined with immunonephelometry on
BNII Analyzer
® (Siemens Healthcare Products GmbH,
Marburg, Germany). The within-subject coefficients of
variation were: 6.9% (apoB), 5.4% (total cholesterol),
and 7.1% (HDL-C). LDL-C was calculated according to
Friedewald’s formula [22].
The DR methodology compares different tests measur-
ing the same underlying physiological variable by deter-
mining the ability of a test to discriminate between
different subjects, and the comparison of discrimination
between different tests as well as the underlying correla-
tion between pairs of tests adjusting for the attenuating
effect of within-subject variation [19]. In a comparison
study where duplicates measurements are performed in
each subject, the measured between-subjects standard
deviation (SDB) is calculated as the SD of the subjects’
mean values calculated from the 2 replicates. The stan-
dard mathematical adjustment to yield the underlying
between-subject SD (SDU) is: SDU = √ (SD
2
B -S D
2
W/2).
The within-subject variance (VW) is calculated for m
r e p e a tt e s t sa s( V W)=S ( x j -xi )
2/(m-1)), the within-sub-
ject SD (SDW) being its square root. The DR represents
the ratio SDU/SDW. Confidence limits for DR’sa n dt h e
testing for equivalence of different DR’s were calculated
and differences were considered significant for p <0 . 0 5 .
Given sample size and number of replicates, the mini-
mal detectable significant difference in DR for the pre-
sent study was calculated as 0.80. Coefficients of
correlation between pairs of tests used to estimate the
severity of dyslipidemia (non-HDL-C and apoB) were
also adjusted to include an estimate of the underlying
correlation, since standard coefficients tend to underes-
timate the true correlation between tests due to the pre-
sence of within-subject variation [19].
Results
The patients’ characteristics are described in Table 1.
Patients’ mean age (1 SD) was 52 (16) years, sex ratio
(M/F) was 63/37, BMI was 26.7 (3.4) kg/m
2,a n d
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patients were in primary macrovascular prevention.
Mean glycaemic control, as reflected by current HbA1c,
was suboptimal at 7.9 (1.6)% (normal value: 4.0-6.0%).
Thirty-one percent of patients were treated with statins
and/or fibrates.
Mean lipid values (day 1) are illustrated in Table 1. In
the combined group, the respective range [percentile 25-
75] for non-HDL-C was 94-284 [117-160] mg/dl, while
the range for apoB was 59-183 [85-113] mg/dl. In
T1DM (n = 23), mean non-HDL-C was 131 (29) mg/dl,
and apoB 91 (21) mg/dl, whereas in T2DM (n = 22),
mean non-HDL-C was 155 (38) mg/dl, and apoB 106
(25) mg/dl. There were significant differences regarding
both parameters between T1DM and T2DM (p =
0.0214 (non-HDL-C) and p = 0.0345 (apoB)). On aver-
age, T2DM patients had higher non-HDL-C values
( a b s o l u t ei n c r e a s e2 4m g / d l ,i . e .+ 1 8 % ) ,w h e r e a st h e y
also had increased apoB level (absolute increase 15 mg/
dl, i.e. +16%).
Figure 1 illustrates the plots of non-HDL-C and apoB
values (day 1 vs. day 2), and the clinical range of lipid
values obtained from the combined T1DM and T2DM
groups. The figure also confirms the homoscedastic
behaviour on repeat testing of the data spread.
The SDU,S D W and DR’s of non-HDL-C and apoB are
shown on Table 2 for T1DM, T2DM and the combined
T1DM and T2DM group. In all three analyses, the DR’s
of both lipid parameters were almost similar (1.87 vs.
2.08 (T1DM); 1.53 vs. 1.51 (T2DM) and 1.76 and 1.83
(all patients), and the observed difference in discrimina-
tory power did not reach statistical significance (p =
0.7052 (T1DM); p = 0.9710 (T2DM), and p = 0.8336 (all
patients), respectively).
The measured Pearson’s product-moment correlation
coefficient between the two tests was very high (0.94),
reaching unity (1.00) once values were correlated after
adjustment for attenuation. T h ep l o t so ft h ed u p l i c a t e
means for non-HDL-C and apoB on day 1 and day 2
are shown for all patients on Figure 2.
The uncorrected linear regression equation relating
non-HDL-C and apolipoprotein B100 was:
apoB (mg dl) 6   non HDL C(mg dl) 12  mg dl /. [ / ] . / =− − + 00 0
Whereas the unbiased equation of equivalence based
on the discriminant ratio methodology relating the two
measurements was:
apoB (mg dl) 65  non HDL C(mg dl) 6 3 mg dl /. [ / ] . / =− − + 0
Discussion
This study demonstrates that in diabetic patients, non-
HDL-C and apolipoprotein B100 performed equally well
to discriminate patients according to their atherogenic
cholesterol values or atherogenic particles number. In
addition, as the underlying correlation between these
two continuous variables reached unity once attenuation
was taken into account, these two measurements may
be used to assess what represents an equivalent underly-
ing biological condition, and that they can substitute for
each other for that respect.
While it is well-recognized that non-HDL-C and
apoB are closely related metabolically, yet there is
ongoing discussion as to whether one should be mea-
sured preferentially over the other, with some consid-
ering apoB as a choice proatherogenic index in
patients with cardiometabolic risk associated with
atherogenic dyslipidemia. Our results confirm the
equivalence of both measurements in their capacity to
rank diabetic patients with a broad spectrum of lipid
values, from normal to frank dyslipidemia with ele-
vated atherogenic cholesterol (non-HDL-C) and/or
atherogenic particles number (apoB).
In this study involving diabetic patients, apoB did not
perform significantly better than non-HDL-C to rank
patients according to atherogenic dyslipidemia. Note-
worthy, lack of significant difference in DRs was not a
bias caused by accretion dilution from pooling T1DM
and T2DM patients with divergent DRs. Whereas non-
HDL-C is derived from the comput of two robust, well-
established measurements methods (total cholesterol
and HDL-C), its DR may be negatively affected by
amplification error from the incorporation of the intrin-
sic imprecisions of two measurements. The small differ-
ence (0.07) in DR that we observed in this study may be
viewed as not clinically meaningful, and there were
no significant differences in discrimination between
Table 1 Patients’ characteristics
N4 5
age years 52.1 (16.2)
sex ratio (M : F) % 63 : 37
BMI kg.m
-2 26.7 (3.4)
diabetes duration years 15.0 (11.4)
HbA1c % 7.9 (1.6)
systolic and diastolic BP mm Hg 133 (17) - 78 (9)
macroangiopathy (CAD &/or PAD) % 17
statin &/or fibrate therapy % 31
total cholesterol mg.dL
-1 199 (38)
LDL-cholesterol mg.dL
-1 116 (31)
HDL-cholesterol mg.dL
-1 56 (17)
non-HDL-cholesterol mg.dL
-1 143 (36)
apolipoprotein B100 mg.dL
-1 98 (24)
triglycerides mg.dL
-1 135 (90)
Results are expressed as means (1 SD) or as proportions (%). BMI: body mass
index; BP: blood pressure; CAD: coronary artery disease; PAD: peripheral artery
disease.
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groups, as well as in the combined group.
Such difference in the DR of non-HDL-C and that of
apoB would nevertheless translate into a meaningful sta-
tistical superiority in the setting of much larger cohort
sizes (i.e. n > 3500 when dealing with duplicate mea-
surements or n > 1800 for triplicates). Thus, the higher
DR of apoB may represent one contributor to higher
performance of determining atherogenic particles num-
ber (apoB) against measuring atherogenic cholesterol
level (non-HDL-C) to predict coronary heart disease, as
observed by Pischon et al. [8]. In a routine clinical
setting, usually dealing with individual risk estimation or
risk stratification between dozens to hundreds of
patients, both non-HDL-C and apoB performed equally
well to discriminate between diabetic patients, and may
be considered as interchangeable surrogates in diabetes.
In the long run, apoB may eventually supersede non-
HDL-C, once a sufficient number of large prospective
studies confirm its superiority in risk prediction, and
after a consensus is reached regarding between-assay
standardization. ApoB determination alleviates the
requirement for fasting conditions, as mentioned in
INTERHEART [13]. Meanwhile, the DR method allows
establishing an unbiased equation of equivalence relating
non-HDL-C to apoB in diabetic subjects. Since the for-
mer is readily available from routine lipid profile in the
fasting state whatever the TG level, this equation allevi-
ates the need to perform additional, and at present
more costly, apoB determination. Once attenuation was
taken into account, both measurements were related by
a line of unity, and had similar performance for ranking
diabetic subjects according to the risk afforded by apoB-
containing particles in scope with the current choles-
terol hypothesis paradigm. As both non-HDL-C and
apoB represent essentially the same underlying biologi-
cal variables in diabetics, both can therefore be substi-
tuted to each other once an unbiased equation of
equivalence is used.
This study has several potential limitations. An easily
refutable one is sample size, as the DR methodology
does not require large samples, with n ≥ 20 for 2 repli-
cates being adequate as long as sample represents
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Figure 1 Plots of untransformed values obtained on day 1 (Xa x i s ) and day 2 (Y axis) for non-HDL-cholesterol (non-HDL-C; left panel)
and apolipoprotein B100 (ApoB; right panel) ratios in n = 45 subjects with diabetes mellitus.
Table 2 Tests precision and discrimination expressed as
underlying between-subject Standard Deviation (SDU),
global within-subject Standard Deviation (SDW), and test
Discriminant Ratio (DR)
SDU SDW DR [CIs]
T1DM (n = 23)
non-HDL-C 27.8 14.9 1.87 [1.30 - 2.78]
apoB100 21.1 10.2 2.08 [1.48 - 3.06]
T2DM (n = 22)
non-HDL-C 36.0 23.5 1.53 [1.00 - 2.36]
apoB100 21.1 14.0 1.51 [0.99 - 2.34]
All patients (n = 45)
non-HDL-C 34.4 19.6 1.76 [1.35 - 2.33]
apoB100 22.3 12.2 1.83 [1.41 - 2.42]
Values from log results of individual tests and means of their duplicates in 45
patients. Confidence intervals [CIs] for DR’s [2.5-97.5%] in square brackets.
apoB100: apolipoprotein B100; C: cholesterol; HDL: high density lipoprotein; SD:
standard deviation; T1DM and T2DM : type 1 and type 2 diabetes mellitus.
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variables under study [19]. As the majority of T1DM are
normolipaemic, combining T1DM and T2DM patients
with significant differences in both non-HDL-C and
apoB, as well as patients with and without lipid-lowering
drug(s), generated an optimal spread of atherogenic
lipids and particles number, as required by the DR
methodology for assessing the performance of a contin-
uous physiological variable. In contrast, the reported
observations need to be verified in other non-diabetic
populations with various severities of (un)treated dyslipi-
demia. A second limitation is that postprandial lipids
were not compared, and the conclusions may not neces-
sarily apply to this state. Yet, neither non-HDL-C nor
apolipoprotein B100 levels are substantially affected by
postprandial excursions in TG-rich lipoproteins, the lat-
ter arising mostly from de novo secretion of gut-derived
apolipoprotein B48-containing chylomicrons.
Although non-HDL-C is derived from two separate bio-
logical assays (total cholesterol and HDL-C) each with
respective imprecision and day-to-day variation, the DR
methodology demonstrates that the discrimination of
non-HDL-C was similar to that of apoB, measured from a
single assay. Non-HDL-C translates into biological mea-
surement of both the number (since it mostly estimates
cholesterol from apoB-carrying lipoproteins) and the com-
bined cholesterol mass of atherogenic apoB-containing
particles. Non-HDL-C determination includes cholesterol
from atherogenic lipoproteins not captured by Friede-
wald’s estimation, such as apoB-carrying remnants not
belonging to LDL or IDL and often found in diabetic
patients and/or in subjects with metabolic syndrome
[14,16,18]. The high agreement that we observed between
methods in this population may also reflect bidirectional
shifts in the distribution of apoB-containing particles size
and cholesterol content seen in diabetic states, including
concomitant increases in TG-poor (such as small-dense
LDL), as well as TG-rich particles.
In parallel to determination of circulating apolipopro-
teins, lipid ratios, still widely reported on lab reports,
incorporate measurements of total or atherogenic lipids
(total C, LDL-C, apoB as numerator) and measurements
of HDL-C or apoA-I to evaluate reverse cholesterol
transport particles as denominator.W ep r e v i o u s l y
reported that with respect to ratio-based lipid markers,
the highest DR’s were those of total C/HDL-C and non-
HDL-C/HDL-C, which were significantly better than
estimated LDL-C/HDL-C. In addition, the apoB/apoA-I
ratio had a non-significantly higher DR than non-HDL-
C and estimated LDL-C/HDL-C [14]. Due to physio-
pathological relevance, robustness, ease and low-cost,
and imperviousness to fasting conditions, the discrimi-
nant ratio of non-HDL-C/HDL-C renders it suitable for
routine ranking of atherogenicity in a given patient with
type 2 diabetes and/or insulin resistance, exposed to
high number of LDL (including small and dense ones),
VLDL and remnants lipoproteins.
With respect to LDL-C and non-LDL-C therapeutic
targets, a recent joint Consensus Statement (American
Diabetes Association and American College of Cardiology
Foundation) suggests new treatment goals for apoB in
patients with atherogenic dyslipidemia and cardiometa-
bolic risk. An apoB level <90 mg/dL was proposed in
patients without diabetes or known CVD but with ≥2
additional major CVD risk factors, or with diabetes and
without major CVD risk factors. An apoB level <80 mg/
dL was suggested for patients with the highest CVD
r i s k ,i . e .k n o w nC V Do rd i a b e t e sp l u s≥1a d d i t i o n a l
major CVD risk factor [18]. With respect to other deter-
minations, there is growing evidence suggesting that
direct measurements of other specific apolipoproteins
may contribute to refine CV risk assessment. Thus, apo-
lipoprotein CIII (apoCIII) level may capture a sizeable
component of TG-attributable CV risk, and apoCIII
measurement may be suited to estimate aspects of hepa-
tic production of a highly-atherogenic VLDL subset and
of their derived atherogenic particles, although at the
moment apoCIII measurement remains in the realm of
research [23-25].
ApoB = 0.65 (non-HDL-C) + 6.3 
R
2 = 0.94
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Figure 2 Plots of means of duplicate measurements obtained
on day 1 and day 2 for non-HDL-cholesterol (non-HDL-C; X
axis) and apolipoprotein B100 (ApoB; Y axis)i nn = 45 subjects
with diabetes mellitus. The line represents the uncorrected linear
regression equation relating non-HDL-C and apolipoprotein B100
[ApoB = 0.60 (non-HDL-C) + 12]. The insert box provides the
unbiased equivalence equation which calculates ApoB from non-
HDL-C based on the discriminant ratio methodology. R
2 represents
the measured Pearson correlation coefficient between tests, prior to
attenuation adjustment.
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the validated DR methodology, that the discrimination of
non-HDL-C is similar to that of apoB in diabetic patients.
Non-HDL-C represents not only a metabolic surrogate,
but is close to a true biological equivalent of apoB in this
specific population. Besides its original usefulness for
estimating LDL-C atherogenicity in hypertriglyceridemic
patients with TG values outside of Friedewald’s formula’s
range, non-HDL-C is an easy and cost-effective means to
estimate apoB levels, while waiting for a consensus
whether to use apoB (i) as an alternative to LDL-C for
biological assessment of hypercholesterolemia, (ii)a sa
residual risk assessment tool in dyslipidemia, or (iii)a s
secondary therapeutic target beyond routine lipids mea-
surement [26-28].
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